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Abstract
 .The first intracellular loop of the G protein-coupled receptors GPCRs is probably the domain that has been studied
least. According to the limited data available, mutations of this region can increase, decrease or not affect receptor-G protein
 .coupling, depending on the receptor. Melanocyte-stimulating hormone MSH receptors with a Ser69Leu mutation of the
first intracellular loop phenotypically confer tobacco color to the coat of mice, and have constitutive activity and enhanced
 .agonist stimulation of adenylyl cyclase. Since the human D1 dopamine receptor D1DR has a serine at the equivalent
position, we were interested to see if this serine is involved in receptor-G protein coupling in a similar fashion. Our
 .site-directed mutagenesis study showed that the replacement of this serine by leucine Ser56Leu in D1DR did not affect the
ability of the receptors to bind ligand or couple to G protein. q 1998 Elsevier Science B.V.
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1. Introduction
A variety of naturally occurring mutations of
GPCRs have been found in several diseases. Some
mutations cause reduction or loss of function, e.g.,
hormone resistance to vasopressin in nephrogenic
w xdiabetes insipidus 1 . Others cause disease states by
w xgaining function, e.g., retinitis pigmentosa 2,3 and
w xJansen-type metaphyseal chondrodysplasia 4 , due to
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constitutively active mutant receptors. Different func-
tional roles have been determined by studying the
structural variations, occurring in different regions of
the receptor proteins. However, studies on the func-
tional role of the first intracellular loop of GPCRs are
lacking. Table 1 lists the mutations that have been
found or made in the first intracellular loop of GPCRs
 .see Section 4 for details . An interesting mutation
that occurs naturally in the first intracellular loop of
 .the melanocyte-stimulating hormone MSH receptor,
w xchanges the pigmentation phenotype in mice 5 . The
Ser69Leu mutation in mice with tobacco coat color
was shown not only to have higher basal level of
activity but also a greater agonist-mediated ability to
stimulate adenylyl cyclase compared to the wild-type
0167-4889r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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Table 1
Summary of the mutations in the first intracellular loop of GPCRs
 .Receptors Mutations Effects on mutant s Ref.
69
w xMSHR WT: KNRNLHSPMYY ›Basal AC activity 5
MUT: KNRNLHLPMYY ›AC Vmax
64
w xb 2AR WT: ERLQTVT xBinding to CYP 9
 .  .MUT: ERL -6- QTVT, ERL -8- QTVT xAC Vmax
64
w xb 2AR WT: KFERLQTVTN xReceptor expression 10
MUT: KFERGQTVTN, KFEGLLTVTN, xAC Vmax
KFEDLETVTN
441
w xTSHR WT: T SHYKLTVPR Binding unchanged 11
MUT: AGQAQLAVPQ xAC Vmax
 .  .  .  .  .  .  .  .TSHR MUT: 1 CNRHLRTVPR, 2 TSHYKLTPTN, 1 , 2 , 5 and 6 : loss of IP3 production; 3 and 4 : xIP3
 .  .  .3 KFERLQTVPR, 4 TSHYKLTVTN, production. All: xAC basal activity and AC V except 5max
 .  .  . w x5 AGQAQLAVPQ, 6 TSHYKLQVPR no change in V 12max
68 71
w xRhodopsin WT: VQHKKLRTPL xTransducin activation 13
MUT: VQHKKL, VQHKKLRL, VQHKKLRAAL
60
w xTxA2-R WT: QGGSHTRSSFLT xIP3 production 14
MUT: QGGSHTLSSFLT
hCRFR II 29 a.a. insert in the first intracellular loop when xAC V and xIP3 productionmax
 . w xcompared to its splicing variant hCRFR I compared To R I 15
w xCCKBR The first intracellular loop of CCKBR was Gained the ability to stimulate adenylyl cyclase 16
replaced by the counterpart of CCKAR
Fig. 1. An alignment of selected GPCRs. The serines in the first
intracellular loop are shaded. The transmembrane domains 1
 .  .TM1 and 2 TM2 are indicated in brackets. D1DR has a serine
at a similar position as MSHR. D1DRsD1 dopamine receptor,
MSHRsmelanocyte-stimulating hormone receptor, D2DRsD2
dopamine receptor, D5DRsD5 dopamine receptor, 5-HT1ARs
5-hydroxytryptamine 1A receptor, a 2ARs a 2 adrenergic recep-
tor, M5AChR s M5 acetylcholine receptor, and IL8R s
interleukin 8 receptor.
receptor. The D1DR has a similar serine residue at
the equivalent position in the first intracellular loop
 .Fig. 1 . We were interested to see if the substitution
of leucine for serine at position 56 of D1DR by
site-directed mutagenesis would also produce consti-
tutive activity andror increased maximal stimulation
of adenylyl cyclase.
2. Materials and methods
2.1. Materials
w 32 x  . w 33 x a- P ATP 800 Cirmmol , a- P ATP 2000
. w3 x w3 x Cirmmol , H SCH23390 and H cAMP 30
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.Cirmmol were from Du PontrNEN. Geneticin
 .G418 , penicillin and streptomycin were from
GIBCOrBRL. Dopamine, GTP, ATP, cAMP and
forskolin were from Sigma. Butaclamol was pur-
 . chased from RBI Natick, MA . Dowex Resin 100–
.200 mesh was from Bio-Rad.
2.2. Cell culture
 .Chinese Hamster Ovarian CHO cells were main-
tained in alpha-MEM containing 10% fetal bovine
serum, 100 Urml penicillin and 100 mgrml strepto-
mycin. Permanent cell lines expressing the wild type
and the mutant receptors were maintained as mono-
layer culture in alpha-MEM containing 10% fetal
bovine serum, 100 Urml penicillin, 100 mgrml
streptomycin and 1 mgrml G418.
2.3. Site-directed mutagenesis of D1DR gene
Mutagenesis was carried out on the human D1
dopamine receptor gene using the PCR as described
w x6 . The PCR products were subcloned into expres-
 .sion vector pRCrCMV Invitrogen and the DNA
sequences encoding the wild type and the mutant
receptors were verified by double-stranded DNA se-
quencing using Sanger’s dideoxynucleotide termina-
tion method with T7 DNA Sequencing Kit Phar-
.macia .
2.4. Permanent transfection of CHO cells with D1DR
genes
Monolayers of cells on Petri dishes at about 50%
confluence were transfected using Ca2q coprecipita-
tion according to the instructions of the manufacturer
 .GIBCOrBRL . Stable cell lines expressing the re-
ceptors were obtained using selection media contain-
w xing G418 and selected as described 6 .
2.5. Ligand binding assays
Radioligand binding was performed essentially as
w xdescribed 6 . The final concentrations in binding
buffer were 75 mM Tris–HCl, 5 mM EDTA, and 5
mM MgCl . Cells were collected in the binding2
buffer by scraping with a rubber policeman. Cell
membrane suspensions were obtained by Polytron
homogenization of the collected cells 6500 rpm for
.20 s . Saturation experiments were carried out in
w3 xtriplicates with H SCH23390 in increasing concen-
trations and nonspecific binding was determined by
 .binding that was not displaced by 1 mM q -
butaclamol.
2.6. Adenylyl cyclase assay
Cell membranes were prepared by Polytron ho-
 .mogenization 6500 rpm for 20 s in binding buffer,
ultracentrifugation of the supernatant at 12 000 rpm
for 15 min to collect membranes, and resuspension of
the membrane pellet in buffer containing 75 mM
Tris–HCl, 8 mM MgCl and 5 mM EDTA. Adenylyl2
cyclase assays were conducted in duplicate as de-
w xscribed 7 at 378C for 20 min, in a total volume of 50
ml of the assay mix, containing 20 mg membrane
protein, 12 mM ATP, 100 mM cAMP, 53 mM GTP,
2.7 mM phosphoenol-pyruvate, 0.2 units of pyruvate
kinase, 1 unit of myokinase and 5 mM ascorbic acid,
w 32 x wwith 0.13 mCi of a- P ATP or 3–5 ml of a-
33 xP ATP, in the presence of indicated concentrations
of dopamine. Reactions were stopped by the addition
of 1 ml of an ice-cold solution containing 0.4 mM
w3 x ATP, 0.3 mM cAMP and H cAMP approximately
.75 000 dpm . The resulting solutions were decanted
directly onto the Dowex columns. The eluate was
then subjected to purification on alumina columns.
Protein concentrations were measured using Bio-Rad
reagents.
2.7. Data analysis
All data were analyzed by nonlinear least squares
regression using the InStat and InPlot GraphPad com-
puter programs.
3. Results
CHO cell lines stably expressing similar levels of
wild type and mutant D1DR were developed and
 .selected Table 2 to determine whether the Ser56Leu
substitution in the first intracellular loop of D1DR
would elicit the same effect as the MSH receptors,
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Table 2
SCH23390 binding parameters for wild type and mutant D1DR
in CHO cells
 .  .Receptor type B fmolrmg K pMmax d
 .  .Wild type 159.8"21.7 11 489.9"75.8 11
 .  .Mutant 214.8"21.4 3 212.6"50.8 3
The values shown in the table are the means"SEM of saturation
binding. The numbers in parentheses indicate the number of
independent experiments that were carried out, each in triplicate.
The data of the wild-type receptor was the summation of eleven
experiments carried out in four cell lines expressing similar levels
of wild-type receptors.
namely an increase in both basal activity and maxi-
 .mal adenylyl cyclase activity V upon agonistmax
stimulation. As shown in Table 2, the cell lines
expressed receptors at about 200 fmolrmg protein,
which is comparable to the physiological receptor
concentration, and demonstrated similar binding
affinity for the D1 selective antagonist
w3 xH SCH23390, with similar dissociation constant
 .K values. Therefore, the introduction of thed
Ser56Leu mutation did not alter the antagonist bind-
ing capability of the D1DR. The observation that
binding of the receptor to ligand was not affected by
the mutation in the first intracellular loop of D1DR is
consistent with previous studies that ligand binding
domains reside on the transmembrane domains for
small molecule ligands and on the extracellular re-
gions of the receptors for large molecules such as
w xpeptides 8 .
We studied the effect of the Ser56Leu mutation on
the effect of basal activity of adenylyl cyclase in
these cells. As shown in Table 3 and Fig. 2, the basal
activity of the cell line expressing the mutant recep-
tors was not increased when compared with the
wild-type receptor cell line. Therefore, no constitu-
Fig. 2. Adenylyl cyclase activation by dopamine in the wild type
and mutant receptors. The curves shown in this figure are repre-
sentatives of 15 cyclase assays performed in four cell lines for
wild-type receptor, and of 5 assays in a cell line expressing
mutant receptors at a similar level. The basal level, V andmax
EC values are listed in Table 3.50
tive activity could be demonstrated in the mutant
receptors as shown in the analogous MSH receptors.
Adenylyl cyclase activity upon maximal stimula-
tion by dopamine was identical in mutant compared
to the wild type D1DR, unlike the observations with
the MSH mutant receptors. The Vmax values of the
wild type and the mutant D1 receptors were almost
 y1identical approximately 100 pmol cAMP mg
y1.  .min Table 3 and Fig. 2 . EC values were also50
similar for the wild type and mutant receptors Table
.3 .
In summary, we did not observe any constitutive
activity nor any enhanced stimulation of adenylyl
cyclase of the mutant D1 receptor as in the case of
MSH receptor. Receptor binding characteristics were
expectedly unaltered as well by the engineered muta-
tion.
Table 3
Basal and dopamine-stimulated adenylyl cyclase activities of wild type and mutant D1DR
y1 y1 y1 y1 .  .  .Receptors Basal pmol cAMP mg min V pmol cAMP mg min EC pMmax 50
 .  .  .Wild type 32.3"3.6 15 88.0"4.9 15 434.5"80.7 15
 .  .  .Mutant 24.5"3.7 5 104.3"15.8 5 284.2"56.0 5
Basal activities and maximal activation of adenylyl cyclase in the cell lines expressing similar receptor levels were determined as
described in the Section 2. The values listed in the table are mean"SEM of the number of experiments indicated in parentheses carried
out in duplicates. The data for the wild-type receptor were the summation of fifteen adenylyl cyclase assays carried out in four cell lines
with approximately the same receptor expression level.
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4. Discussion
Characterizations of the functional role of the first
intracellular loop of GPCRs are generally lacking.
However, in a limited number of studies, outlined in
Table 1, this domain has been shown to play a critical
role in receptor expression and receptor-G protein
coupling in at least some receptors. One of the mu-
tant receptors that is of particular interest has been
the MSH receptor. A naturally occurring mutant re-
 .ceptor Ser69Leu in the first intracellular loop found
in tobacco-coat mice showed constitutive activity and
greater activation of its effector, adenylyl cyclase,
than the wild type when expressed in human 293
w xcells 5 .
w xIn b 2-adrenergic receptors, Kobilka et al. 9
showed that insertion of 4–8 amino acid residues into
the middle of the first intra-cellular loop led to a
marked reduction in binding of the antagonist
cyanopindolol and in the maximal agonist activation
of adenylyl cyclase, although activation occurred with
the same EC as in the wild-type receptor. It is50
probable that normal folding and conformation of the
receptor protein was disturbed by these insertions. In
another study of the first intracellular loop of b 2-
w xadrenergic receptors, O’Dowd et al. 10 found that
the single substitution of Leu64 by Gly resulted in a
receptor with a 10-fold increased binding affinity for
agonist isoproterenol, but normal binding for
cyanopindolol. This mutant receptor had an apprecia-
bly lower level of expression, accounting for its
reduced potency and efficacy of cyclase stimulation.
In the same study, substitutions of the amino acids
flanking position 64 had similar but more deleterious
effects on receptor expression, thus preventing mean-
ingful adenylyl cyclase activation parameters to be
obtained.
 .In the thyrotropin TSH receptor, the results are
w xcontroversial. Chazenbalk et al. 11 reported that a
nonconserved substitution mutant involving the first
intracellular loop caused the total loss of the TSH-in-
duced cAMP response. However, Kosugi and Mori
w x12 reported that the first cytoplasmic loop is impor-
tant for phosphoinositide signaling but not for ago-
nist-induced adenylyl cyclase activation when re-
placed with the corresponding homologous amino
acids from a1- and b 2-ARs.
In the characterization of mutant rhodopsins re-
sponsible for autosomal dominant retinitis pigmen-
w xtosa, Min et al. 13 discovered that deletion and
replacement of two amino acids in the first intra-
cellular loop resulted in a complete loss and a reduc-
tion of light-dependent transducin activation, respec-
tively.
A mutation in the first cytoplasmic loop of the
 .thromboxane A2 TXA2 receptor was demonstrated
w xby Hirata et al. 14 in affected members of two
unrelated families with a mild bleeding disorder char-
acterized by defective platelet response to TXA2. In
this receptor the replacement of Arg60 by Leu, a
highly conserved basic residue among GPCRs, caused
impaired ability to induce agonist-mediated PI hydro-
lysis.
w xNabhan et al. 15 reported that corticotropin-re-
 .leasing factor CRF receptor has two alternatively
spliced forms. The two splice variants are identical
except for a 29-amino-acid insert present in the first
intracellular loop of the type II receptor. When ex-
pressed in COS cells, type II CRF receptor had low
binding affinity, a weak cAMP response and low
inositol phosphate generation, suggesting that this
receptor is weakly coupled to G protein, as a result of
the change in the first intracellular loop.
w xWu et al. 16 constructed a series of chimeric
receptors containing different parts of cholecys-
tokinin-A and -B receptors CCK-AR and CCK-BR,
.respectively . One of the chimera, CCK-BA ,ICL-1
which consisted mainly of CCK-BR sequence with
only the first intracellular loop being replaced by the
corresponding CCK-AR amino acid residues, gained
the function to couple to the Gs as with CCK-AR,
although to a less extent.
In summary, mutations in the first intracellular
loop, whether occurring naturally or engineered by in
vitro mutagenesis, may have variable effects on the
function of different receptors, causing increased e.g.,
. MSH and CCKBR , decreased e.g., b 2AR, some
.TSHR mutants, rhodopsin and hCRFRII or no change
 .e.g., some TSHR mutants in receptor-G protein
coupling. Our study showed that Ser56 in the first
intracellular loop of the D1DR does not influence
receptor–effector coupling. The differences that these
various receptors manifest may relate to the relative
position of residues within the intracellular loop,
determined by the overall three dimensional architec-
ture of the receptor, and may not therefore be directly
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comparable with each other. These findings empha-
size the importance of studying structure–function
determinants of GPCRs individually rather than to
generalize from one receptor to another based on the
common topography of GPCRs. Our efforts to eluci-
date the final determinants of the relationship be-
tween the structure and function of G protein-coupled
receptors are still at a preliminary stage, until the
structures of these receptors are definitively revealed
by crystallography.
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